Recently, treatment with exedin-4 (a long-acting agonist of GLP-1R) was shown to reduce development of diabetic retinopathy ([DR], one of the commonest complications of diabetes) in animal models of diabetes, [13–15]. The gene discussed is GLP1R; the disease is diabetic retinopathy.